These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 34253646

  • 21. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [Abstract] [Full Text] [Related]

  • 22. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.
    Kiss B, Némethy Z, Fazekas K, Kurkó D, Gyertyán I, Sághy K, Laszlovszky I, Farkas B, Kirschner N, Bolf-Terjéki E, Balázs O, Lendvai B.
    Drug Des Devel Ther; 2019 Jan; 13():3229-3248. PubMed ID: 31571826
    [Abstract] [Full Text] [Related]

  • 23. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S, Saini SK, Zhou G, Hobrath JV, Padmalayam I, Zhai L, Bostwick JR, Antonio T, Reith ME, McDowell S, Cho E, McAleer L, Taylor M, Luedtke RR.
    J Med Chem; 2014 Aug 28; 57(16):7042-60. PubMed ID: 25126833
    [Abstract] [Full Text] [Related]

  • 24. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
    Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW.
    J Pharmacol Exp Ther; 1995 Dec 28; 275(3):1355-66. PubMed ID: 8531103
    [Abstract] [Full Text] [Related]

  • 25. Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44.
    Weber M, Chang WL, Durbin JP, Park PE, Luedtke RR, Mach RH, Swerdlow NR.
    Pharmacol Biochem Behav; 2009 Aug 28; 93(2):141-7. PubMed ID: 19426754
    [Abstract] [Full Text] [Related]

  • 26. Antagonism of the effects of (+)-PD 128907 on midbrain dopamine neurones in rat brain slices by a selective D2 receptor antagonist L-741,626.
    Bowery BJ, Razzaque Z, Emms F, Patel S, Freedman S, Bristow L, Kulagowski J, Seabrook GR.
    Br J Pharmacol; 1996 Dec 28; 119(7):1491-7. PubMed ID: 8968560
    [Abstract] [Full Text] [Related]

  • 27. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine Receptor.
    Free RB, Cuoco CA, Xie B, Namkung Y, Prabhu VV, Willette BKA, Day MM, Sanchez-Soto M, Lane JR, Laporte SA, Shi L, Allen JE, Sibley DR.
    Mol Pharmacol; 2021 Oct 28; 100(4):372-387. PubMed ID: 34353882
    [Abstract] [Full Text] [Related]

  • 28. [3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain.
    Gackenheimer SL, Schaus JM, Gehlert DR.
    J Pharmacol Exp Ther; 1995 Sep 28; 274(3):1558-65. PubMed ID: 7562534
    [Abstract] [Full Text] [Related]

  • 29. 1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.
    Micheli F, Bernardelli A, Bianchi F, Braggio S, Castelletti L, Cavallini P, Cavanni P, Cremonesi S, Dal Cin M, Feriani A, Oliosi B, Semeraro T, Tarsi L, Tomelleri S, Wong A, Visentini F, Zonzini L, Heidbreder C.
    Bioorg Med Chem; 2016 Apr 15; 24(8):1619-36. PubMed ID: 26951894
    [Abstract] [Full Text] [Related]

  • 30. Domperidone: review of pharmacology and clinical applications in gastroenterology.
    Reddymasu SC, Soykan I, McCallum RW.
    Am J Gastroenterol; 2007 Sep 15; 102(9):2036-45. PubMed ID: 17488253
    [Abstract] [Full Text] [Related]

  • 31. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
    Langlois X, Megens A, Lavreysen H, Atack J, Cik M, te Riele P, Peeters L, Wouters R, Vermeire J, Hendrickx H, Macdonald G, De Bruyn M.
    J Pharmacol Exp Ther; 2012 Jul 15; 342(1):91-105. PubMed ID: 22490380
    [Abstract] [Full Text] [Related]

  • 32. Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.
    Luedtke RR, Mishra Y, Wang Q, Griffin SA, Bell-Horner C, Taylor M, Vangveravong S, Dillon GH, Huang RQ, Reichert DE, Mach RH.
    ACS Chem Neurosci; 2012 Dec 19; 3(12):1050-62. PubMed ID: 23259040
    [Abstract] [Full Text] [Related]

  • 33. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
    Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AK, Hagan JJ.
    J Pharmacol Exp Ther; 2000 Sep 19; 294(3):1154-65. PubMed ID: 10945872
    [Abstract] [Full Text] [Related]

  • 34. Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonist.
    Corbin AE, Pugsley TA, Akunne HC, Whetzel SZ, Zoski KT, Georgic LM, Nelson CB, Wright JL, Wise LD, Heffner TG.
    Pharmacol Biochem Behav; 1998 Feb 19; 59(2):487-93. PubMed ID: 9476999
    [Abstract] [Full Text] [Related]

  • 35. Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms.
    Schetz JA, Chu A, Sibley DR.
    J Pharmacol Exp Ther; 1999 May 19; 289(2):956-64. PubMed ID: 10215675
    [Abstract] [Full Text] [Related]

  • 36. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
    Gobert A, Rivet JM, Audinot V, Cistarelli L, Spedding M, Vian J, Peglion JL, Millan MJ.
    J Pharmacol Exp Ther; 1995 Nov 19; 275(2):899-913. PubMed ID: 7473181
    [Abstract] [Full Text] [Related]

  • 37. The discovery of PD 89211 and related compounds: selective dopamine D4 receptor antagonists.
    Pugsley TA, Shih YH, Whetzel SZ, Zoski K, Van Leeuwen D, Akunne H, Mackenzie R, Heffner TG, Wustrow D, Wise LD.
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb 19; 26(2):219-26. PubMed ID: 11817497
    [Abstract] [Full Text] [Related]

  • 38. BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties.
    Gylys JA, Wright RN, Nicolosi WD, Buyniski JP, Crenshaw RR.
    J Pharmacol Exp Ther; 1988 Mar 19; 244(3):830-7. PubMed ID: 2978041
    [Abstract] [Full Text] [Related]

  • 39. The histamine H3R and dopamine D2R/D3R antagonist ST-713 ameliorates autism-like behavioral features in BTBR T+tf/J mice by multiple actions.
    Venkatachalam K, Eissa N, Awad MA, Jayaprakash P, Zhong S, Stölting F, Stark H, Sadek B.
    Biomed Pharmacother; 2021 Jun 19; 138():111517. PubMed ID: 33773463
    [Abstract] [Full Text] [Related]

  • 40. Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets.
    Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, Cox BF, Brioni JD, Moreland RB.
    Pharmacol Biochem Behav; 2005 May 19; 81(1):211-9. PubMed ID: 15894081
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.